Acumen Pharmaceuticals (ABOS) Expected to Post Quarterly Earnings on Monday

Acumen Pharmaceuticals (NASDAQ:ABOS) is expected to be posting its Q3 2026 results before the market opens on Monday, October 26th. Analysts expect Acumen Pharmaceuticals to post earnings of ($0.43) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, October 26, 2026 at 8:00 AM ET.

Acumen Pharmaceuticals (NASDAQ:ABOS) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.09). On average, analysts expect Acumen Pharmaceuticals to post ($1.60) EPS for the current fiscal year and ($1.67) EPS for the next fiscal year.

Acumen Pharmaceuticals Stock Performance

Shares of ABOS opened at $2.02 on Wednesday. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.47 and a quick ratio of 2.47. Acumen Pharmaceuticals has a one year low of $1.50 and a one year high of $3.60. The firm has a market capitalization of $145.72 million, a P/E ratio of -1.24 and a beta of 0.33. The business has a fifty day moving average of $2.55 and a 200 day moving average of $2.48.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on ABOS shares. Citigroup increased their target price on Acumen Pharmaceuticals from $4.00 to $5.00 and gave the company a “buy” rating in a report on Tuesday, September 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a research report on Friday, October 2nd. BTIG Research restated a “buy” rating and set a $8.00 price target on shares of Acumen Pharmaceuticals in a research note on Wednesday, September 16th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Acumen Pharmaceuticals in a research report on Thursday, September 17th. Finally, Wall Street Zen lowered shares of Acumen Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Acumen Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $7.00.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer’s disease. The company’s research is based on the amyloid-beta oligomer hypothesis, which holds that soluble forms of amyloid-beta may contribute to the synaptic dysfunction and neurodegeneration associated with the disease.

Acumen’s lead product candidate is sabirnetug, also known as ACU193, an investigational humanized monoclonal antibody designed to selectively target toxic soluble amyloid-beta oligomers while seeking to avoid binding to monomeric amyloid-beta.